Ignite Creation Date:
2024-05-06 @ 2:32 AM
Last Modification Date:
2024-10-26 @ 11:19 AM
Study NCT ID:
NCT02064816
Status:
COMPLETED
Last Update Posted:
2018-09-20
First Post:
2014-02-13
Brief Title:
A Study of Rebif in Subjects With Relapsing Multiple Sclerosis
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Study Overview
Official Title:
Multicenter Open-label 12 Week Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a Rebif Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RELIEF
Brief Summary:
This is an open-label multi-center 12-week randomized controlled parallel group Phase 4 study to assess whether the morning administration of interferon beta 1a Rebif leads to a lower severity of flu-like symptoms FLS as compared to the evening administration in subjects with relapsing multiple sclerosis RMS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2013-004450-21 | EUDRACT_NUMBER | None | None |